Suppressive efficacy of roxithromycin against human peripheral-blood mononuclear cells stimulated with hemolytic streptococci superantigen

European Journal of Pharmacology

Volumn 602, Issue 2-3, 2009, Pages 439-447

  Kamogawa, Sho ^a   Kagami, Keisuke ^a   Maeda, Masaki ^b   Arai, Kae ^c   Okubo, Yukari ^c   Tsuboi, Ryoji ^c   Hirano, Toshihiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b Bohsei Pharmacy   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytokine; Glucocorticoid; Hemolytic streptococci; JNK activity; Peripheral blood mononuclear cell; Roxithromycin; Superantigen

Indexed keywords

BETAMETHASONE; CYTOKINE; ENTEROTOXIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MACROLIDE; ROXITHROMYCIN; STRESS ACTIVATED PROTEIN KINASE; SUPERANTIGEN;

ADULT; ARTICLE; BACTERIAL COLONIZATION; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELPER CELL; HEMOLYTIC STREPTOCOCCUS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOREGULATION; IN VITRO STUDY; MALE; MEASUREMENT; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; PSORIASIS; SUPERNATANT;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BETAMETHASONE; CELL PROLIFERATION; CONCANAVALIN A; CYTOKINES; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION; HEMOLYTIC AGENTS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKOCYTES, MONONUCLEAR; MALE; ROXITHROMYCIN;

EID: 58149142818     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.11.045     Document Type: Article

References (43)

1. Aiba S., Uddin Z., Nakagawa S., Sugawara S., Rikiishi H., Kumagai K., and Tagami H. Decreased IL-10 production by psoriatic peripheral blood mononuclear cells stimulated with streptococcal superantigen. Exp. Dermatol. 11 (2002) 337-343
2. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., and Krueger J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 13 (1999) 752-759
3. Barker J.N., Karabin G.D., Stoof T.J., Sarma V.J., Dixit V.M., and Nickoloff B.J. Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. J. Dermatol. Sci. 2 (1991) 106-111
4. Bata-Csorgo Z., Hammerberg C., Voorhees J.J., and Cooper K.D. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95 (1995) 317-327
5. Behnam S.M., Behnam S.E., and Koo J.Y. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J. Drugs Dermatol. 4 (2005) 189-194
6. Charakida A., Dadzie O., Teixeira F., Charakida M., Evangelou G., and Chu A.C. Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. Expert Opin. Pharmacother. 7 (2006) 597-606
7. Culić O., Eraković V., and Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 429 (2001) 209-229
8. Edmead C.E., Patel Y.I., Wilson A., Boulougouris G., Hall N.D., Ward S.G., and Sansom D.M. Induction of activator protein (AP)-1 and nuclear factor-kappaB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. J. Immunol. 157 (1996) 3290-3297
9. Fakhri S., Tulic M., Christodoulopoulos P., Fukakusa M., Frenkiel S., Leung D.Y., and Hamid Q.A. Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model. Laryngoscope 114 (2004) 887-892
10. Fukushima H., Hirano T., Shibayama N., Miwa K., Ito T., Saito M., Sumida H., Oyake S., Tsuboi R., and Oka K. The role of immune response to Staphylococcus aureus superantigens and disease severity to the sensitivity to tacrolimus in atopic dermatitis. Int. Arch. Allergy Immunol. 141 (2006) 281-289
11. Fukushima H., Hirano T., and Oka K. Staphylococcus aureus superantigens decreases FKBP51mRNA expression and cell response to suppressive efficacy of glucocorticoid in human peripheral blood mononuclear cells: Possible implication of MAPK pathways. Eur. J. Pharmacol. 570 1-3 (2007) 222-228
12. Galioto G.B., Ortisi G., Mevio E., Sassella D., Bartucci F., and Privitera G. Roxithromycin disposition in tonsils after single and repeated administrations. Antimicrob. Agents Chemother. 32 (1988) 1461-1463
13. Haczku A., Alexander A., Brown P., Assoufi B., Li B., Kay A.B., and Corrigan C. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J. Allergy Clin. Immunol. 93 (1994) 510-519
14. Hand W.L., King-Thompson N., and Holman J.W. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 31 (1987) 1553-1557
15. Hauk P.J., Hamid Q.A., Chrousos G.P., and Leung D.M. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J. Allergy Clin. Immunol. 105 (2000) 782-787
16. Haycock K.A., Roth R., and Gagnon J. Statview (1994), Abacus Concepts, Berkeley, Calif.
17. Hirano T. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int. Immunopharmacol. 7 (2007) 3-22
18. Hirano T., Oka K., Takeuchi H., Sakurai E., Matsuno N., Nagao T., and Kozaki M. Clinical significance of glucocorticoid pharmacodynamics assessed by anti-lymphocyte action in kidney transplantation: marked difference between prednisolone and methylprednisolone. Transplantation 57 (1994) 1341-1348
19. Hirano T., Oka K., and Tamaki T. Gramicidin as a potent immunosuppressant for organ transplantation: suppression of human lymphocyte blastogenesis in vitro and prolongation of heart allograft survival in the rat. J. Pharmacol. Exp. Ther. 273 (1995) 223-229
20. Hirano T., Oka K., Takeuchi H., Kozaki K., Matsuno N., Nagao T., Kozaki M., Ichikawa M., Yoshida M., Umezawa Y., Hirata M., Ohi T., and Koga M. Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis and psoriasis: possible implications for individual therapeutic efficacy. Clin. Pharmacol. Ther. 62 (1997) 652-664
21. Hirano T., Oka K., Umezawa Y., Hirata M., Oh-I T., and Koga M. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine-efficacy in psoriasis. Clin. Pharmacol. Ther. 63 (1998) 465-470
22. Hirano T., Akashi T., Keira T., Oka K., Ihoya N., and Yoshida M. Clinical impact of cyclosporine cellular-pharmacodynamics in minimal change nephrotic syndrome. Clin. Pharmacol. Ther. 68 (2000) 532-540
23. Hirano T., Akashi T., Kido T., Oka K., Shiratori T., and Miyaoka M. Immunosuppressant pharmacodynamics on peripheral-blood mononuclear cells from patients with ulcerative colitis. Int. Immunopharmacol. 2 (2002) 1055-1063
24. Kirkham B.W., Corkill M.M., Davison S.C., and Panayi G.S. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J. Rheumatol. 18 (1991) 821-825
25. Koike T., Yamagishi H., Hatanaka Y., Fukushima A., Chang J.W., Xia Y., and Fields M. Chandler P; Iwashima MA novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation. J. Biol. Chem. 278 (2003) 15685-15692
26. Komine M., and Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J. Dermatol. 27 (2000) 508-512
27. Koyama M., Tateno M., and Shirotuka M. Absorption, metabolism and excretion of RU 28965 in human. Chemotherapy 36 (1988) 164-183
28. Kudoh S., Uetake T., Hagiwara K., Hirayama M., Hus L.H., Kimura H., and Sugiyama Y. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25 (1987) 632-642 (in Japanese)
29. Leung D.Y., Travers J.B., and Giorno R. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 96 (1995) 2106-2112
30. Li L.B., Goleva E., Hall C.F., Ou L.S., and Leung D.Y. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J. Allergy Clin. Immunol. 114 (2004) 1059-1069
31. Norris D. Mechanisms of action of topical therapies and the rationale for combination therapy. J. Am. Acad. Dermatol. 53 (2005) 17-25
32. Ohshima A., Takigawa M., and Tokura Y. CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement. Eur. J. Dermatol. 11 (2001) 410-415
33. Pacifico A., Daidone R., and Peris K. A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 153-157
34. Polat M., Lenk N., Yalcin B., Gür G., Tamer E., Artuz F., and Alli N. Efficacy of erythromycin for psoriasis vulgaris. Clin, Exp. Dermatol. 32 (2007) 295-297
35. Puri S.K., and Lassman H.B. Roxithromycin: a pharmacokinetic review of a macrolide. J. Antimicrob. Chemother. 20 (1987) 89-100
36. Rasmussen J.E. The relationship between infections with group A beta hemolytic streptococci and the development of psoriasis. Pediatr. Infect. Dis. J. 19 (2000) 153-154
37. Schlaak J.F., Buslau M., Jochum W., Hermann E., Girndt M., Gallati H., Meyer zum Büschenfelde K.H., and Fleischer B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102 (1994) 145-149
38. + subsets. J. Invest. Dermatol. 111 (1998) 1072-1078
39. Tamaoki J., Kadota J., and Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am. J. Med. 117 (2004) 5S-11S
40. Taylor J.E., Ross D.A., and Goodacre J.A. Group A streptococcal antigens and superantigens in the pathogenesis of autoimmune arthritis. Eur. J. Clin. Invest. 24 (1994) 511-521
41. Tsai W.C., and Standiford T.J. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr. Pharm. Des. 10 (2004) 3081-3093
42. Uchiyama T., Imanishi K., Araake M., Saito S., Yan X.-J., Fujikawa H., Igarashi H., and Yamaura N. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules. J. Immunol. 143 (1989) 3175-3182
43. Wise R., Kirkpatrick B., Ashby J., and Andrews J.M. Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing. Antimicrob. Agents Chemother. 31 (1987) 1051-1053